DealForma and Pragma Bio Webinar
The webinar, featuring Dr. Orly Levitan, CBO of Pragma Bio, provided insights into biopharma dealmaking, funding trends, and the role of AI in drug discovery. Dr. Levitan emphasized strategies for small biopharma companies, including capital efficiency, outsourcing non-core activities, and leveraging AI/ML tools for rapid discovery. Get access to the recording here!
Key Highlights
- Venture: $11.9B in Q3 2024 venture investment for biotech
- Licensing: 98 licensing deals in Q3 2024, $1.6B upfront, $37.5B total
- AI: $6.1B in 2024 YTD venture investment for life sciences AI companies
- Pragma Bio Insights: Leveraging computational tools to achieve key milestones efficiently and form value-driven partnerships.
- 2025 Outlook: Anticipation of more active M&A and partnership activity, with increased interest in platform deals and non-dilutive funding.
